Lexeo Therapeutics has posted updated data in Friedreich ataxia (FA) patients, linking a gene therapy to improvements on outcomes the biotech plans to use as co-primary endpoints in a ...

Truist has initiated coverage of Larimar Therapeutics (NASDAQ:LRMR) with a buy rating, citing an "asymmetric" risk/reward ahead of regulatory updates for its drug candidate nomla for Friedreich ...

Net loss was $32.7 million or $0.99 per share (basic and diluted) for the three months ended March 31, 2025, compared to $21.7 million or $0.77 per share (basic and diluted) for the three months ...

Additionally, SGT-212 for Friedreich’s Ataxia is expected to begin dosing its first participant in the second half of 2025, while the IND for SGT-501 targeting catecholaminergic polymorphic ...

In this video, Khalaf Bushara, MD, FRCP, highlights the greatest challenges in Friedreich's ataxia care and management.

To expand his research on patients with Friedreich's ataxia, Bidichandani is collaborating with David R. Lynch, M.D., Ph.D., of Children's Hospital of Philadelphia, who shares a portion of the grant.

Friedreich’s ataxia appears in the teenage years with balance and walking problems and can lead to heart issues, vision and hearing loss, and other symptoms. The disorder is inherited, caused by ...

Session ID: 2025-05-02:8f3912a8e89c700fbf07bfb0 Player Element ID: V1a92bad6_4471_4d5b_86c3_0e32123c1dcb_6369445265112 ...